It is one of several RNA vaccine candidates that are being studied in parallel for selection to advance to a trial of their safety and efficacy
Moves by the US and UK to secure supplies from Sanofi and partner GlaxoSmithKline Plc, and another pact between Japan and Pfizer Inc., are the latest in a string of agreements
BioNTech and Pfizer on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy
The move pushes the New York-based pharmaceutical giant and its German partner closer to bringing a vaccine to market, and places them alongside frontrunners like Moderna Inc
The report comes at the start of a busy week of US pharmaceutical earnings, with investors focusing on updates on the development of vaccines and treatments for the pandemic
The study is expected to include about 120 sites globally and could include up to 30,000 participants. It will include regions heavily impacted by Covid-19
Revenue stood at Rs 514.89 crore against Rs 544.40 crore for the same period a year ago
The companies will not receive any money from the government unless their vaccine succeeds in large clinical trials
US drugmaker Pfizer and German biotech firm BioNTech reported additional data from their experimental Covid-19 vaccine that showed it was safe and induced an immune response in patients
The companies said the data also demonstrated an induction of high level of T-cell response against the novel coronavirus
Deals follow a previously announced agreement with AstraZeneca for the firm to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford
The research said patients treated with the vaccine candidate produced nearly 1.8 to 2.8 fold greater levels of antibodies that could neutralise SARS-CoV-2
With its other potential candidates still in the earliest stage of testing, Pfizer aims to open a large-scale study this summer but can't yet say which shot is best to include
A Covid-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trials
The company has already signed deals with the US government to create enough manufacturing capacity to produce more than 1 billion doses of its vaccine through 2021
Pfizer and German partner BioNTech SE (22UAy.F) said on Tuesday they have begun delivering doses of their coronavirus vaccine candidates for initial human testing in the United States.
The AIIMS director stresses on the need to have good and well-conducted research trials before the therapy is recommended for routine use
The company has fixed May 8, 2020 as the record date for ascertaining eligible shareholders who would get the dividend of Rs 320 per share.
We should question the wisdom and morality of a system that silently condemns millions of human beings to suffering
The trial, only the fourth worldwide of a vaccine targeting the virus, will be initially conducted on 200 healthy people aged 18 to 55 years in first stage